ABAnne Gry Bentzen

Anne Gry Bentzen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anne Gry Bentzen has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Faecal incontinence after chemoradiotherapy in anal cancer survivors: Long-term results of a national cohort

    by Anne Gry Bentzen, Marianne G. Guren, Barthold Vonen, Eva H. Wanderås, Gunilla Frykholm, Tom Wilsgaard, Olav Dahl, Lise Balteskard


  • Impaired health-related quality of life after chemoradiotherapy for anal cancer: Late effects in a national cohort of 128 survivors

    by Anne Gry Bentzen, Lise Balteskard, Eva Hoff Wanderås, Gunilla Frykholm, Tom Wilsgaard, Olav Dahl, Marianne Grønlie Guren

    Background. Chemoradiotherapy is an effective treatment for anal cancer, yet from follow-up many survivors seem to suffer from late effects. Data of long-term health-related quality of life (HRQOL) in anal cancer survivors are limited, and there is a growing interest in cancer survivorship. Material and methods. A national cohort of all anal cancer survivors treated with curative chemoradiotherapy in 2000–2007 was invited to a cross-sectional study. Of 199 eligible survivors, 128 (64%) returned the questionnaires, the median time since diagnosis was 66 months. The median age was 61 years and 79% were women. HRQOL was evaluated with EORTC questionnaires QLQ-C30 and QLQ-CR29, and neurotoxicity with the Scale of Chemotherapy-Induced Neurotoxicity. An age- and sex-matched reference group of volunteers (n = 269) not treated for pelvic cancer answered the same questionnaires. Results from QLQ-C30 of the reference group were compared to Norwegian and Dutch normative data. Results. The mean scores of anal cancer survivors were poorer compared to volunteers and normative data. Anal cancer survivors reported significant impairment of function, especially social and role function, compared to the volunteers (difference ≥ 20 points, p < 0.001). Survivors had markedly increased scores for fatigue, dyspnoea, insomnia and diarrhoea (difference ≥ 15 points, p < 0.001). The global quality of life was significantly reduced (difference 15 points, p < 0.001). Anal cancer survivors had increased stool frequency, more buttock pain, flatulence, faecal incontinence, impotence (males), dyspareunia and reduced sexual interest (females) (difference ≥ 15 points, p < 0.001). There was increased frequency of tinnitus in survivors treated with cisplatin-based chemotherapy (p = 0.004). Conclusions. Survivors after chemoradiotherapy for anal cancer have significant long-term impairment of HRQOL. Reduced social, role and sexual function, and increased diarrhoea, incontinence for gas and stools, and buttock pain were commonly reported. Increased awareness of this may lead to better management of late effects and better care for cancer survivors.


  • Chemoradiotherapy of Anal Carcinoma: Survival and Recurrence in an Unselected National Cohort

    by Anne Gry Bentzen, Marianne G. Guren, Eva H. Wanderås, Gunilla Frykholm, Kjell M. Tveit, Tom Wilsgaard, Olav Dahl, Lise Balteskard


    • 29 November 2007
      • Vol. 127  (23) , 3102-5

    [Recurrence of rectal cancer--treatment in Norwegian hospitals].

    by Anne Gry Bentzen, Barthold Vonen, Johan N Wiig, Lise Balteskard

    The aim of this study was to examine if Norwegian surgeons had a passive attitude to treatment of patients with local recurrence of rectal cancer after primary treatment and if attitudes to treatment differed between hospitals. All 46 departments for gastrointestinal surgery in Norway answered a questionnaire detailing their policy for workup, referral and treatment of patients with pelvic recurrence after surgery for rectal cancer. All hospitals used MRI for evaluation of the pelvis. Most clinics initially considered the patients potentially curable. Many wished to refer the patients to hospitals with more competence. Most patients in Norway are treated in eight different departments. Most of the surgeons give preoperative chemoradiotherapy before surgical resection of the local recurrence. There seems to be a reasonable consensus among Norwegian surgeons about treatment of recurrent rectal cancer. The doctors themselves have to a certain degree centralized the treatment. Patients with recurrent rectal cancer should be discussed in multidisciplinary teams.